Dementia care 'on cusp of a revolution' as new hope given to millions

Dementia care is on the brink of a major revolution, with new hope emerging from recent research advancements, according to health experts. However, they caution that several obstacles must still be addressed to fully harness the potential of promising treatments. The latest report on dementia, released on World Alzheimer's Day, highlights a new era of care that could mirror the rapid progress seen in cancer treatment.

Currently, 158 potential therapies are undergoing trials, but several challenges could delay their arrival.

Chris Lynch, acting chief executive of Alzheimer’s Disease International, expressed optimism, stating, "This is a moment of real hope for dementia research." "After decades of frustration, clinical trials have shown for the first time that new treatments can slow the progression of Alzheimer's disease, and a burgeoning pipeline of treatment trials brings real hope." However, he also warned that key barriers, such as insufficient recruitment of trial participants, could hinder progress.

Active trials require approximately 55,000 participants, but an estimated pool of 350,000 participants is needed to meet regulatory and scientific requirements. The recruitment process is hindered by factors such as low awareness of the value of dementia trials, limited GP referrals, travel costs, and a high eligibility bar. Lynch emphasized that blood-based biomarkers could revolutionize recruitment, drastically reducing screening costs and enabling recruitment on a scale not seen before.

He also noted that the oncology field provides valuable lessons in trial development and referral pathways.

One of the main challenges in dementia trials is the lack of diversity among participants, particularly in high-income countries. Most trial participants are white, which undermines the scientific robustness of the studies. Researchers in the United Arab Emirates (UAE) are working on local trials that could set a new benchmark for dementia treatment in the Arab world. The Emirati Genome Programme has enlisted a million Emiratis to offer their genetic data, accelerating the development of new dementia drugs.

African countries, particularly those in sub-Saharan Africa, face a desperate need for localized clinical dementia research. In Kenya and other rural areas, most clinical trials take place in urban or metropolitan zones, leaving rural populations underserved. Zul Merali, the founding director of the Aga Khan University Brain & Mind Institute, stressed the importance of better targeting rural populations and providing practical support, such as transportation to clinical trial centers, to increase recruitment and participation from underserved communities.

In Cuba, researchers have recently completed a cluster-randomized trial involving primary care clinics across the country. Instead of relying on expensive specialist infrastructure, the program trained ordinary family doctors to recognize dementia earlier and more confidently. Over 12 months, diagnosis rates significantly improved in the intervention clinics, suggesting that even basic symptoms like mild confusion and brain fog, combined with a family history of dementia, should prompt further investigation.

Dr. Derk Krieger, a neurological specialist at Fakeeh University Hospital and the lead of the Brain Health Programme at Recognition Health in Dubai, expressed, "We are witnessing a sea change in Alzheimer's care. For the first time, we have treatments that can slow the underlying disease, not just relieve symptoms." Krieger emphasized the need for research to reflect the patients being treated, noting the distinctive genetic, metabolic, cultural, and lifestyle characteristics of the Middle East that should be studied.

He also called for a shift from treating dementia late in life to protecting brain health throughout life, proposing that prevention measures should begin as early as age 40 to avoid serious health issues by age 60.